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ABSTRACT
Antimicrobial susceptibility testing was performed on 3627 isolates of Escherichia coli and 180 isolates of
Shigella spp. collected in rural locations from 875 Egyptian children with diarrhoea between 1995 and
2000. The cumulative rates of resistance for E. coli and Shigella spp. were high (respectively, 68.2% and
54.8% for ampicillin, 24.2% and 23.5% for ampicillin–sulbactam, 57.2% and 42.5% for trimethoprim–
sulphamethoxazole, and 50.9% and 75.4% for tetracycline). Non-enterotoxigenic E. coli (NETEC) isolates
had a consistently higher level of antimicrobial resistance than did enterotoxigenic E. coli (ETEC)
isolates. Trend testing showed significant decreases in resistance to ampicillin, ampicillin–sulbactam
and tetracycline among all E. coli isolates. Increasing rates of resistance were observed for trimethoprim–
sulphamethoxazole in ETEC isolates and Shigella spp., but not in NETEC isolates. Low levels of
resistance were observed for all other antimicrobial agents tested. Overall, high levels, but decreasing
trends, of resistance to commonly used antimicrobial agents were detected among isolates of E. coli and
Shigella spp. from children in rural Egypt.
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INTRODUCTION
Infectious diarrhoea continues to cause significant
morbidity and mortality among children world-
wide [1]. This problem is especially acute in
developing countries, where c. 25% of all deaths
in children aged < 5 years are associated with an
acute infectious diarrhoeal episode [1]. Two of the
most important bacterial agents of childhood
diarrhoea in developing countries are enterotoxi-
genic Escherichia coli (ETEC) and Shigella spp.
[2,3]. Globally, c. 400 million ETEC-associated
episodes of diarrhoea occur annually, with an
estimated 700 000 deaths [4]. Those most at risk of
ETEC-associated diarrhoea in developing coun-
tries are children aged < 5 years, travellers and
deployed military personnel [5–7]. In addition to
ETEC, an estimated 165 million episodes of
infection with Shigella spp. occur annually, with
c. 1.1 million deaths [3].
Numerous reports have described antibiotic
resistance among pathogenic and non-pathogenic
bacteria [8–11], and have documented increasing
numbers of treatment failures associated with
pathogens showing decreased susceptibility
to commonly prescribed antimicrobial agents
[8,12–16]. Although there have been few previ-
ous reports focusing on diarrhoeal disease, the
high frequency with which antibiotics are used
empirically to treat diarrhoeal disease suggests
that there might also be high rates of treatment
failure associated with enteric infections [17,18].
Worldwide hospital-based surveillance systems
(e.g., Alexander Project, SENTRY, MYSTIC [19])
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have demonstrated that antibiotic resistance con-
tinues to increase in both developed and devel-
oping countries. However, such surveillance
systems are based primarily on sterile-site recov-
ery of pathogens from hospitalised patients. In
contrast, the primary objective of the present
study was to assess the level of antibiotic resist-
ance and temporal trends among Shigella spp. and
ETEC recovered from children in Egypt with
community-acquired diarrhoea. A secondary
objective was to compare the antibiotic resistance
rates found in ETEC and non-ETEC isolates
during the study period.
MATERIALS AND METHODS
Study population and surveillance
Enteropathogens were recovered during 1995 and 2000 from
Egyptian infants and children residing in the Abu Homos
district, c. 40 km south-west of Alexandria, Egypt, during one
of three prospective diarrhoeal studies conducted by US Naval
Research Unit No. 3 (NAMRU-3). The first (February 1995 to
February 1998) was a paediatric longitudinal diarrhoeal
surveillance study [20]; the second was an on-going birth-
cohort diarrhoeal study started in February 1998; and the third
(October 1998 to September 2001) was a phase III ETEC vaccine
trial. Informed consent was obtained from the parents of all
subjects, and the research was conducted in compliance with
all applicable Federal Regulations governing the protection of
human subjects in research.
For all three studies, study investigators visited each
enrolled child at home twice-weekly. If a ‘loose, liquid or
bloody stool’ was reported by the parents, a faecal sample and
rectal swab were collected, and the child was referred to a
study physician for evaluation and possible treatment [21]. In
addition, a questionnaire was completed for each subject at the
time of specimen collection to obtain data regarding demo-
graphics, severity of illness, food and drink consumption,
illness among family members, previous antibiotic use and
other putative exposure variables.
Rectal swabs were inoculated into Cary–Blair transport
medium and, together with the faecal samples, were stored in
a cool box and transported to a field laboratory. Fresh stools
were inoculated into buffered glycerol saline, matched with
the rectal swabs, and refrigerated at 4C before transport (also
at 4C) to the microbiology laboratory at NAMRU-3.
Laboratory isolation and identification
Standard laboratory procedures were used for the isolation of
enteric pathogens, with the identity of isolates being con-
firmed with the API 20E system (Analytab Products, New
York, NY, USA). Commercially available antisera (Becton
Dickinson, Sparks, MD, USA) were used to serotype all
recovered Shigella isolates. Up to five individual colonies of
presumptive E. coli from each agar plate were assayed for the
production of heat-labile toxin (LT) and heat-stable toxin (ST)
with two different enzyme immunoassays [22,23]. Isolates
that produced toxin(s) were defined as ETEC, while non-toxin
producers were defined as non-enterotoxigenic E. coli (NE-
TEC).
Isolate selection
As a substantial number of E. coli isolates were collected over
the 6-year study period, a sampling scheme was used to select
an unbiased sample for antibiotic susceptibility testing. First,
the isolates were stratified according to their originating study
site (three-level stratification). Then, within the study site,
stratification was by month and year of collection. Finally,
isolates from each month were selected by simple random
sampling. As there were significantly fewer isolates of Shigella
spp., all isolates collected between January 1995 and December
2000 were tested.
Antimicrobial susceptibility testing
Antimicrobial susceptibilities were tested by the disk diffusion
method [24], and were interpreted according to National
Committee for Clinical Laboratory Standards guidelines [25]
as either susceptible, intermediate or resistant. For analysis, the
intermediate and resistant categories were grouped together as
‘non-susceptible’. Multiresistance was defined as non-suscep-
tibility to at least three families of antibiotics, including
ampicillin, trimethoprim–sulphamethoxazole and tetracycline.
E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853
were used as quality control strains.
Statistical analysis
Differences in proportions for binary variables were analysed
with the Mantel–Haenszal chi-square test. To assess trends in
susceptibility across the study period, logistic regression was
used to determine whether antibiotic resistance (binary out-
come) was dependent on the year of collection, while adjusting
for potential confounders. To control for parameter estimate
bias associated with repeated measures among the study
cohorts, a generalised estimating equation regression model
was used, which reported parameter estimates and p values.
Statistical significance was set at p < 0.05 (two-sided). All data
were analysed with SAS v. 8.0 software (SAS Institute, Cary,
NC, USA).
RESULTS
Study population
In total, 874 children participated in the three
major cohort studies. Of these, 365 children were
enrolled during 1995–2000 as part of the diar-
rhoea surveillance study, with the remaining
children participating in either the birth-cohort
study (n = 197) or the ETEC vaccine efficacy trial
(n = 312).
Overall, 3178 representative isolates of E. coli
were tested during the 6-year period of the
present study (Table 1). During this period, 180
isolates of Shigella spp. were recovered from 193
children (Table 2). There was significant variation
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in the recovery of Shigella spp., but the predom-
inant species was Shigella flexneri, accounting for
‡ 50% of the isolates recovered each year. The
isolation rate of Shigella dysenteriae remained fairly
constant throughout the 6-year period.
The median age and the categorised age
groups of the children yielding E. coli and
Shigella spp. did not demonstrate significant
year-to-year variation, with the exception of
1998 (the year in which the birth-cohort study
began enrolling newborn infants). The gender
distribution did not change significantly among
the group from which E. coli was isolated
(Table 1), but there was variation among the
group yielding Shigella spp. (Table 2). Overall,
there was an initial increase in use of antecedent
antibiotics, peaking (13.5% of children) for the
E. coli group in 1998, followed by decreases in
1999 (8%) and 2000 (9%) (Table 1). For the group
from whom Shigella spp. were isolated, antece-
dent antibiotic use was reported only during
1999 (8.7% of children).
Table 2. General characteristics of children from whom
Shigella spp. were isolated
Characteristic 1995 1996 1997 1998 1999 2000
Median age (months)a 16 15 15 7 15 15
Age in months (%)
< 6 5.2 0 10.0 42.9 4.3 0
6–11 18.2 25.0 15.0 42.9 17.4 20.0
12–23 59.7 41.7 50.0 14.3 78.3 60.0
> 23 16.9 33.3 25.0 0 0 20.0
Male (%) 57.1 41.7 70.0 71.4 34.8 80.0
Previous antibiotic use (%)b 0 0 0 0 8.7 0
Total isolates (n) 87 12 23 7 46 5
Shigella dysenteriae 12.6 16.7 17.4 14.3 19.6 20.0
Shigella flexneri 55.2 83.3 65.2 58.7 50.0 60.0
Shigella boydii 0 0 0 0 8.7 20.0
Shigella sonnei 32.2 0 17.4 0 21.7 0
aMean age was calculated based on the age at the time of specimen collection.
bAntibiotic taken within the 3 days before collection of the specimen.
Table 1. General characteristics of children from whom
Escherichia coli was isolated
Characteristic 1995 1996 1997 1998 1999 2000
Median age (months)a 13 13 14 8 14 12
Age in months (%)
< 6 20.5 17.8 18.5 27.5 7.7 18.5
6–11 23.9 25.2 25.7 49.8 27.3 28.7
12–23 44.3 35.2 33.5 20.8 60.7 37.8
> 23 11.3 21.8 22.3 1.9 4.3 15.0
Male (%) 55.3 58.5 52.5 47.8 48.7 54.6
Previous antibiotic use (%)b 5.4 8.5 9.5 13.5 7.6 9.1
Total isolates (n) 591 540 579 207 700 561
ETEC (%) 44.2 41.5 48.9 32.4 32.3 25.3
aMean age was calculated based on the age at the time of specimen collection.
bAntibiotic taken within the 3 days before collection of the specimen.
Table 3. Antibiotic resistance found
in Escherichia coli isolates from 1995
to 2000, stratified according to toxin
production
Antibiotic
Toxin
production 1995 1996 1997 1998 1999 2000
Trend test
(b ⁄p)
Total ETEC 323 258 330 72 255 126
NETEC 369 336 304 157 570 497
% resistance
Ampicillin ETEC 64.1 69.8 57.6 73.6 58.2 64.1 ) 0.04 ⁄ 0.2
NETEC 72.1 78.0 79.3 80.9 61.9 69.6 ) 0.1 ⁄< 0.0001
Ampicillin–
sulbactam
ETEC 17.3 22.1 17.3 19.4 14.5 9.6 ) 0.1 ⁄ 0.01
NETEC 24.9 34.8 42.1 35.7 23.2 22.9 ) 0.09 ⁄ 0.004
Trimethoprim–
sulphamethoxazole
ETEC 39.6 60.1 57.9 65.3 47.8 52.1 0.05 ⁄ 0.1
NETEC 57.2 67.6 68.8 73.3 53.0 57.3 ) 0.07 ⁄ 0.004
Tetracycline ETEC 36.5 61.6 36.1 43.1 35.3 36.5 ) 0.08 ⁄ 0.02
NETEC 55.8 63.7 66.1 61.8 50.4 53.7 ) 0.08 ⁄ 0.0009
Amikacin ETEC 0 0 0 0 0 0
NETEC 0 0 1.3 0 0.4 0
Aztreonam ETEC 0.3 0.8 1.5 2.8 1.2 1.3
NETEC 0.8 0.8 0.6 4.6 0.6 1.2
Cefepime ETEC 0 0 0 0 0 0.6
NETEC 0 0 0 0 0 0
Ceftriaxone ETEC 0 0 0 0 0 0.6
NETEC 0.3 0.6 0.7 0 0 0
Gentamicin ETEC 0 0 0 0 0 0.6
NETEC 0.3 0.6 1.3 0 0 0.2
Nalidixic acid ETEC 0.3 1.6 0.6 0 0 0.6
NETEC 1.1 1.2 4.0 1.9 1.4 2.8
Ciprofloxacin ETEC 0 0 0 0 0 0
NETEC 0 0.3 0.7 0.6 0.2 0.6
Ticarcillin–
clavulanic acid
ETEC 5.3 9.7 4.6 8.3 4.7 7.1
NETEC 19.2 11.3 19.4 20.4 11.1 9.3
Ceftazidime ETEC 0.3 0.8 0.3 1.4 0.4 0
NETEC 0.3 0 1.0 1.3 0.2 0
Imipenem ETEC 0 0 0 0 0 0
NETEC 0 0 0 0 0 0
Multiresistanta ETEC 25.7 41.9 25.8 30.6 19.6 27.6 ) 0.08 ⁄ 0.03
NETEC 48.8 50.3 53.6 51.6 33.5 33.8 ) 0.1 ⁄< 0.0001
ETEC, enterotoxigenic E. coli; NETEC, non-enterotoxigenic E. coli.
aResistant to at least three families of antibiotics, including ampicillin, trimethoprim–sulphamethoxazole and
tetracycline.
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Antibiotic susceptibility trends
Overall, there were modest annual changes in the
percentage of isolates resistant to antibiotics that
are commonly available and used in developing
countries against both E. coli and Shigella spp.
(Tables 3 and 4). There was minimal resistance
to quinolones (nalidixic acid, ciprofloxacin),
advanced-generation cephalosporins (ceftazi-
dime, ceftriaxone, cefepime), carbapenems (imi-
penem), monobactams (aztreonam) and
aminoglycosides (amikacin, gentamicin). The lack
Table 4. Antibiotic resistance found
in isolates of Shigella spp. from 1995
to 2000
Antibiotic Organism 1995 1996 1997 1998 1999 2000
Trend test
(b ⁄p)
Total 87 12 23 7 46 5
S. boydii 0 0 0 0 4 1
S. dysenteriae 11 2 4 1 9 1
S. flexneri 48 10 15 6 23 3
S. sonnei 28 0 4 0 10 0
% resistance
Ampicillin S. boydii – – – – 50.0 0
S. dysenteriae 0 0 100 100 11.1 100
S. flexneri 97.9 90.0 60.0 33.3 78.3 66.7 ) 1.2 ⁄ 0.002
S. sonnei 3.7 – 0 – 10.0 –
Ampicillin–
sulbactam
S. boydii
S. dysenteriae
–
0
–
0
–
0
–
0
0
0
0
0
S. flexneri 52.1 50.0 26.7 0 26.1 66.7 ) 0.2 ⁄ 0.1
S. sonnei 0 – 0 – 0 –
Trimethoprim–
sulphamethoxazole
S. boydii
S. dysenteriae
–
0
–
0
–
0
–
100
100
33.3
0
100
S. flexneri 14.6 50.0 20.0 16.7 47.8 66.7 0.2 ⁄ 0.6
S. sonnei 96.3 – 75.0 – 90.0 –
Tetracycline S. boydii – – – – 75.0 0
S. dysenteriae 0 0 100 0 22.2 100 ) 1.0 ⁄ 0.009
S. flexneri 95.8 100 60.0 33.3 79.9 66.7
S. sonnei 96.3 – 75.0 – 100 –
Amikacin S. boydii – – – – 0 0
S. dysenteriae 0 0 0 0 0 0
S. flexneri 4.2 0 6.7 0 0 0
S. sonnei 0 – 0 – 0 –
Aztreonam S. boydii – – – – 0 0
S. dysenteriae 9.1 0 0 100 0 0
S. flexneri 4.2 0 0 0 0 0
S. sonnei 0 – 0 – 0 –
Cefepime S. boydii – – – – 0 0
S. dysenteriae 0 0 0 0 0 0
S. flexneri 0 0 0 0 0 0
S. sonnei 0 – 0 – 0 –
Ceftriaxone S. boydii – – – – 0 0
S. dysenteriae 0 0 0 100 0 0
S. flexneri 0 0 0 0 0 0
S. sonnei 0 – 0 – 0 –
Gentamicin S. boydii – – – – 0 0
S. dysenteriae 0 0 0 0 0 0
S. flexneri 2.1 0 0 0 0 0
S. sonnei 0 – 0 – 0 –
Nalidixic acid S. boydii – – – – 14.3 0
S. dysenteriae 0 0 0 0 0 0
S. flexneri 0 0 0 0 0 0
S. sonnei 0 – 0 – 0 –
Ciprofloxacin S. boydii – – – – 0 0
S. dysenteriae 0 0 0 0 0 0
S. flexneri 0 0 0 0 0 0
S. sonnei 0 – 0 – 0 –
Ticarcillin–
clavulanic acid
S. boydii
S. dysenteriae
–
0
–
0
–
0
–
0
0
0
0
0
S. flexneri 0 0 0 0 4.4 33.3
S. sonnei 0 – 0 – 0 –
Ceftazidime S. boydii – – – – 0 0
S. dysenteriae 0 0 0 0 0 0
S. flexneri 0 0 0 0 0 0
S. sonnei 0 – 0 – 0 –
Imipenem S. boydii – – – – 0 0
S. dysenteriae 0 0 0 0 0 0
S. flexneri 0 0 0 0 0 0
S. sonnei 0 – 0 – 0 –
Multiresistanta S. boydii – – – – 0 0
S. dysenteriae 0 0 0 0 25.0 0
S. flexneri 14.6 40.0 20.0 16.7 34.8 66.7 0.3 ⁄ 0.4
S. sonnei 3.6 – 0 – 0 –
aResistant to at least three families of antibiotics, including ampicillin, trimethoprim–sulphamethoxazole and
tetracycline.
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of annual resistance data for these antibiotics
precluded valid trend analysis.
Decreasing trends of antibiotic resistance were
noted among ETEC isolates for ampicillin, ampi-
cillin–sulbactam, tetracycline and the multiresis-
tance phenotype (Table 3). The only agent that
demonstrated an increasing resistance trend
among ETEC isolates was trimethoprim–sulpha-
methoxazole, but this trend was not significant.
Among NETEC isolates, there was a consistent
decrease in the resistance trends across the study
period for ampicillin, ampicillin–sulbactam, trim-
ethoprim–sulphamethoxazole, tetracycline and
the multiresistance phenotype (Table 3). Among
the isolates of Shigella spp., only S. flexneri had
enough data points to enable valid trend analysis;
this showed increasing resistance to trimetho-
prim–sulphamethoxazole, and the multiresistance
phenotype, but decreasing resistance to ampicillin,
ampicillin–sulbactam, and tetracycline (Table 4).
DISCUSSION
In agreement with reports from other developing
countries [9,26–32], the present study demonstra-
ted very high rates of resistance in E. coli and
Shigella spp. to antibiotics that are commonly
available in Egypt. These resistance rates
remained fairly stable throughout the 6-year
study period. Previous studies have demonstra-
ted a strong correlation between antibiotic resist-
ance and high rates of antibiotic use, with a
reduction in antibiotic use being followed by a
reduction in resistance [33–35]. In contrast, the
present study found low antecedent antibiotic
use, perhaps indicating that the results reflect
community-based exposure to and acquisition of
resistant enteric flora, as opposed to the devel-
opment of antibiotic resistance following individ-
ual consumption of antibiotics. Walson et al. [36]
demonstrated in Nepal that community-based
factors (e.g., population density, community
and ⁄ or regional consumption of antibiotics, dis-
tance from allopathic health care, and other
unmeasured factors) provided strong, or stron-
ger, predictors of antibiotic resistance carriage
than the consumption of antibiotics by individu-
als. The data in the present study also supported
a ‘community exposure’ model, and the popula-
tion studied had open access to antibiotics from
local pharmacies. Therefore, it is quite possible
that significant antibiotic misuse was occurring in
the population, thereby selecting and maintaining
large numbers of resistant bacteria in the com-
munity. The observed lack of resistance to anti-
biotics used rarely in the community supports
this model.
The data revealed several statistically signifi-
cant decreasing trends in antibiotic resistance in
the period 1995–2000, but these should be viewed
in the context of a rural developing region in
which high levels of antibiotic resistance among
enteric pathogens were common in the commu-
nity. There was no indication of a dramatic
increase or decrease in rates of resistance among
isolates of E. coli and Shigella spp. during the 6-
year period. However, there appeared to be a
slight increase in low-level resistance to newer
antibiotics during the last 2 years of the study
(Table 3).
The regression trend analysis was adjusted,
according to age and previous antibiotic use
because of potential confounding of these two
variables. Age was associated with antibiotic
resistance, in that younger children were more
likely than older children to yield resistant strains.
It was also demonstrated that age was associated
with previous antibiotic use, with younger chil-
dren receiving antibiotic treatment more often for
a variety of infectious diseases. Similarly, Howard
et al. [33] reported that the rate of resistance in
isolates of E. coli from urinary tract infections
decreased as the age of children increased. Previ-
ous antibiotic use among the present sample was
difficult to assess, but the limited data indicated
that there was an association between previous
antibiotic use and either the recovery of resistant
isolates or age.
The higher levels of resistance in NETEC,
compared to ETEC, was somewhat disconcerting,
as NETEC strains, forming part of the normal
intestinal flora, could serve as quasi-permanent
reservoirs of transmissible antibiotic resistance
determinants [9,37]. The continual shedding of
antibiotic-resistant E. coli from the normal flora
into an environment where selection exists for
antibiotic resistance could result in community-
wide cycling of resistant non-pathogenic enteric
flora among the population. A previous study [38]
concluded that previous antibiotic use by patients
in long-term care institutions explained the recov-
ery of antibiotic-resistant E. coli, but that condi-
tions which facilitate spread may be more
important in sustaining high resistance in such
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an environment. The overall resistance found in
Shigella spp. reflected the rates of resistance found
in other developing countries [26,29–32,39,40], but
could not be analysed further because of the
relatively small number of isolates recovered in
the present study.
A significant limitation of the present study
was that it was not possible to determine anti-
biotic resistance rates among isolates from ado-
lescents and adults. The observed rates may be
over-estimates of the true community-based anti-
biotic resistance rates for this region, as antibiotic
use tends to decrease with age. Other limitations
were the unavailability of information regarding
other variables (e.g., previous hospitalisation,
other underlying disease) that are associated with
the isolation of antibiotic-resistant bacteria, and
the use of isolates from children participating in
three separate studies. However, the children
studied were all residents of the same village, and
standardised methods (i.e., active surveillance,
sample and data collection, laboratory testing,
etc.) were used for all three studies.
In developing countries, antibiotic resistance
has been linked with inappropriate use of anti-
biotics, over-the-counter availability of antibiot-
ics, lack of health care personnel with adequate
training, poor-quality drugs and poor sanitary
conditions [41]. Continued surveillance of anti-
biotic resistance, especially in community-based
populations within developing countries, is cru-
cial to alleviate morbidity and mortality among
those living in and visiting these countries.
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